Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults
| dc.contributor.author | Gorse, G.J. | |
| dc.contributor.author | Baden, L.R. | |
| dc.contributor.author | Wecker, M. | |
| dc.contributor.author | Newman, M.J. | |
| dc.contributor.author | Ferrari, G. | |
| dc.contributor.author | Weinhold, K.J. | |
| dc.contributor.author | Livingston, B.D. | |
| dc.contributor.author | Villafana, T.L. | |
| dc.contributor.author | Li, H. | |
| dc.contributor.author | Noonan, E. | |
| dc.contributor.author | Russell, N.D. | |
| dc.date.accessioned | 2012-12-31T14:07:21Z | |
| dc.date.accessioned | 2017-10-19T12:11:36Z | |
| dc.date.available | 2012-12-31T14:07:21Z | |
| dc.date.available | 2017-10-19T12:11:36Z | |
| dc.date.issued | 2008 | |
| dc.description.abstract | We evaluated EP HIV-1090 vaccine, a DNA plasmid encoding 21 cytotoxic T-lymphocyte (CTL) epitopes of human immunodeficiency virus type 1 (HIV-1) and the pan-DR helper T-lymphocyte epitope (PADRE), in a dose escalation, randomized, double-blinded, placebo-controlled Phase 1 trial. Vaccine, at 0.5, 2.0, or 4.0mg doses, or placebo was injected four times over 6 months. Forty-two healthy, HIV-1-uninfected adults were enrolled. Using an interferon-gamma ELISPOT assay, a response to PADRE was detected in one vaccine recipient. Three vaccine recipients raised anti-HIV-1 CD8+ CTL measured by chromium-release assay. The vaccine was safe and well-tolerated, but only weakly immunogenic. | en_US |
| dc.identifier.citation | 26(2):215-23 | en_US |
| dc.identifier.uri | http://197.255.68.203/handle/123456789/2076 | |
| dc.language.iso | en | en_US |
| dc.publisher | Vaccine Journal | en_US |
| dc.title | Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults | en_US |
| dc.type | Article | en_US |